Table 1.
Mortality data from selected studies on patients with cancer and COVID-19.
| Countries | Total number of patients with cancer and COVID-19 | Number of deaths | Death rate | Time period of study (2020) | Refs. |
|---|---|---|---|---|---|
| USA, Canada, Spain | 928 | 121 | 13% | 17 March−16 April | （Kuderer et al., 2020) |
| Italy | 909 | 150 | 16.5% | Up–30 March | (Trapani et al.，2020) |
| UK Coronavirus CancerMonitoring Project | 800 | 226 | 28% | 18 March–26 April | (Lee et al., 2020) |
| New York, USA | 423 | 51 | 12% | 10 March–7 April | (Robilotti et al., 2020b)) |
| TERAVOLT Registry | 400 | 141 | 35.5% | 26 March−12 April | (Horn et al., 2020) |
| New York, USA | 218 | 61 | 28% | 18 March−8 April | (Mehta et al., 2020) |
| Europe chronic lymphatic leukaemia | 190 | 55 | 28 March−22 May | (Scarfo et al., 2020) | |
| Brazilian National Cancer Institute | 181 | 60 | 33.1% | 30 April−26 May | (deMelo et al., 2020) |
| Gustave Roussy Cancer Campus,Villejuif, France | 137 | 20 | 14.6% | 14 March−15 April | (Fabrice et al., 2020) |
| China | 105 | 12 | 11.4% | 1 January−24 February | (Mengyuan et al., 2020) |
| New York, USA | 102 | 25 | 25% | 12 March−6 May | (Luo et al., 2020a)) |